Despite advances in diagnostic tools and therapeutic options, treatment resistance remains
a challenge for many cancer patients. Recent studies have found evidence that autophagy …

Since reprogramming energy metabolism is considered a new hallmark of cancer, tumor
metabolism is again in the spotlight of cancer research. Many studies have been carried out …

Background The efficacy and safety of multikinase inhibitor anlotinib have been confirmed in
the treatment of advanced non-small cell lung cancer (NSCLC). However, the direct …

Sunitinib is one of the most widely used targeted therapeutics for renal cell carcinoma
(RCC), but acquired resistance against targeted therapies remains a major clinical …

Numerous modifications of the well-known antimalarial drug primaquine, both at the
quinoline ring and at the primary amino group, have been reported, mostly to obtain …

Abstract The Food and Drug Administration has lately approved atezolizumab, anti-
programmed death ligand 1 (PD-L1), to be used together with nanoparticle albumin-bound …

摘要目的: 研究spautin-1 (一种自噬抑制剂) 是否能抑制舒尼替尼诱导的肾癌细胞的自噬以及对
舒尼替尼诱导的肾癌细胞凋亡的影响. 方法: 以肾癌细胞系786-O 细胞为模型, Western Blot …

Sažetak Four classes of aminoquinoline derivatives were prepared: primaquine ureas 1a–f,
primaquine bis-ureas 2a–f, chloroquine fumardiamides 3a–f and mefloquine fumardiamides …

In recent years, the paradigm cancer management has shifted towards a targeted approach.
Among the newly targeted anticancer therapies are ponatinib and sunitinib, small molecules …